• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

从骨髓增生异常综合征(MDS)转化为急性髓系白血病(AML)时可检测到的FLT3内部串联重复(FLT3-ITD)或RAS突变预示预后极差。

Detectable FLT3-ITD or RAS mutation at the time of transformation from MDS to AML predicts for very poor outcomes.

作者信息

Badar Talha, Patel Keyur P, Thompson Philip A, DiNardo Courtney, Takahashi Koichi, Cabrero Monica, Borthakur Gautam, Cortes Jorge, Konopleva Marina, Kadia Tapan, Bohannan Zach, Pierce Sherry, Jabbour Elias J, Ravandi Farhad, Daver Naval, Luthra Raja, Kantarjian Hagop, Garcia-Manero Guillermo

机构信息

Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.

Department of Hematopathology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.

出版信息

Leuk Res. 2015 Dec;39(12):1367-74. doi: 10.1016/j.leukres.2015.10.005. Epub 2015 Oct 19.

DOI:10.1016/j.leukres.2015.10.005
PMID:26547258
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC4822515/
Abstract

BACKGROUND

The molecular events that drive the transformation from myelodysplastic syndromes (MDS) to acute myeloid leukemia (AML) have yet to be fully characterized. We hypothesized that detection of these mutations at the time of transformation from MDS to AML may lead to poorer outcomes.

METHODS

We analyzed 102 MDS patients who were admitted to our institution between 2004 and 2013, had wild-type (wt) FLT3-ITD and RAS at diagnosis, progressed to AML, and had serial mutation testing at both the MDS and AML stages.

RESULTS

We detected FLT3-ITD and/or RAS mutations in twenty-seven (26%) patients at the time of transformation to AML. Twenty-two patients (81%) had RAS mutations and five (19%) had FLT3-ITD mutations. The median survival after leukemia transformation in patients who had detectable RAS and/or FLT3-ITD mutations was 2.4 months compared to 7.5 months in patients who retained wt RAS and FLT3-ITD (hazard ratio [HR]: 3.08, 95% confidence interval [CI]: 1.9-5.0, p<0.0001). In multivariate analysis, FLT3-ITD and RAS mutations had independent prognostic significance for poor outcome.

摘要

背景

驱动骨髓增生异常综合征(MDS)向急性髓系白血病(AML)转化的分子事件尚未完全明确。我们推测在MDS向AML转化时检测到这些突变可能导致较差的预后。

方法

我们分析了2004年至2013年间入住我院的102例MDS患者,这些患者诊断时为野生型(wt)FLT3-ITD和RAS,进展为AML,并且在MDS和AML阶段均进行了系列突变检测。

结果

在转化为AML时,我们在27例(26%)患者中检测到FLT3-ITD和/或RAS突变。22例(81%)患者有RAS突变,5例(19%)有FLT3-ITD突变。检测到RAS和/或FLT3-ITD突变的患者白血病转化后的中位生存期为2.4个月,而保留wt RAS和FLT3-ITD的患者为7.5个月(风险比[HR]:3.08,95%置信区间[CI]:1.9 - 5.0,p<0.0001)。在多变量分析中,FLT3-ITD和RAS突变对不良预后具有独立的预后意义。

相似文献

1
Detectable FLT3-ITD or RAS mutation at the time of transformation from MDS to AML predicts for very poor outcomes.从骨髓增生异常综合征(MDS)转化为急性髓系白血病(AML)时可检测到的FLT3内部串联重复(FLT3-ITD)或RAS突变预示预后极差。
Leuk Res. 2015 Dec;39(12):1367-74. doi: 10.1016/j.leukres.2015.10.005. Epub 2015 Oct 19.
2
Acquisition of FLT3 or N-ras mutations is frequently associated with progression of myelodysplastic syndrome to acute myeloid leukemia.FLT3或N-ras突变的获得常与骨髓增生异常综合征进展为急性髓系白血病相关。
Leukemia. 2004 Mar;18(3):466-75. doi: 10.1038/sj.leu.2403274.
3
Internal tandem duplication of fms-like tyrosine kinase 3 is associated with poor outcome in patients with myelodysplastic syndrome.FMS样酪氨酸激酶3的内部串联重复与骨髓增生异常综合征患者的不良预后相关。
Cancer. 2004 Sep 1;101(5):989-98. doi: 10.1002/cncr.20440.
4
FLT3 internal tandem duplication during myelodysplastic syndrome follow-up: a marker of transformation to acute myeloid leukemia.骨髓增生异常综合征随访期间的FLT3内部串联重复:向急性髓系白血病转化的标志物
Cancer Genet Cytogenet. 2008 Jun;183(2):89-93. doi: 10.1016/j.cancergencyto.2008.02.006.
5
Prognostic implications of NPM1 mutations and FLT3 internal tandem duplications in Egyptian patients with cytogenetically normal acute myeloid leukemia.NPM1突变和FLT3内部串联重复在埃及细胞遗传学正常的急性髓系白血病患者中的预后意义
Hematology. 2014 Jan;19(1):22-30. doi: 10.1179/1607845413Y.0000000085. Epub 2013 Nov 25.
6
The FLT3 internal tandem duplication mutation at disease diagnosis is a negative prognostic factor in myelodysplastic syndrome patients.疾病诊断时的 FLT3 内部串联重复突变是骨髓增生异常综合征患者的一个负预后因素。
Leuk Res. 2022 Feb;113:106790. doi: 10.1016/j.leukres.2022.106790. Epub 2022 Jan 11.
7
Different clinical importance of FLT3 internal tandem duplications in AML according to FAB classification: possible existence of distinct leukemogenesis involving monocyte differentiation pathway.根据FAB分类,FLT3内部串联重复在急性髓系白血病中的不同临床意义:涉及单核细胞分化途径的独特白血病发生机制可能存在。
Ann Hematol. 2009 Nov;88(11):1089-97. doi: 10.1007/s00277-009-0733-7. Epub 2009 Mar 19.
8
Prognostic significance of FLT3 ITD and D835 mutations in AML patients.FLT3内部串联重复(ITD)和D835突变在急性髓系白血病(AML)患者中的预后意义。
Hematol J. 2003;4(1):41-6. doi: 10.1038/sj.thj.6200224.
9
The Role of FLT3-ITD Mutation on de Novo MDS in Chinese Population.FLT3-ITD 突变在中国人群初发性骨髓增生异常综合征中的作用。
Clin Lymphoma Myeloma Leuk. 2019 Feb;19(2):e107-e115. doi: 10.1016/j.clml.2018.11.006. Epub 2018 Nov 12.
10
Aberrant expression of CD7 in myeloblasts is highly associated with de novo acute myeloid leukemias with FLT3/ITD mutation.原始粒细胞中CD7的异常表达与伴有FLT3/ITD突变的初发急性髓系白血病高度相关。
Am J Clin Pathol. 2008 Apr;129(4):624-9. doi: 10.1309/NRTX9AKXHR5JBT93.

引用本文的文献

1
RAS mutations in myeloid malignancies: revisiting old questions with novel insights and therapeutic perspectives.髓系恶性肿瘤中的RAS突变:用新见解和治疗前景重新审视老问题。
Blood Cancer J. 2024 Apr 24;14(1):72. doi: 10.1038/s41408-024-01054-2.
2
Mutations in myeloid transcription factors and activated signaling genes predict chronic myeloid leukemia outcomes.髓系转录因子和激活信号基因的突变可预测慢性髓性白血病的结局。
Blood Adv. 2024 May 28;8(10):2361-2372. doi: 10.1182/bloodadvances.2023012127.
3
Acute myeloid leukemia: from NGS, through scRNA-seq, to CAR-T. dissect cancer heterogeneity and tailor the treatment.急性髓细胞白血病:从 NGS 到 scRNA-seq,再到 CAR-T。解析癌症异质性并定制治疗方案。
J Exp Clin Cancer Res. 2023 Oct 6;42(1):259. doi: 10.1186/s13046-023-02841-8.
4
Therapeutic Targets in Myelodysplastic Neoplasms: Beyond Hypomethylating Agents.骨髓增生异常综合征的治疗靶点:超越去甲基化药物
Curr Hematol Malig Rep. 2023 Jun;18(3):56-67. doi: 10.1007/s11899-023-00693-9. Epub 2023 Apr 13.
5
An Updated Overview of the Role of CYP450 during Xenobiotic Metabolization in Regulating the Acute Myeloid Leukemia Microenvironment.CYP450 在调节急性髓系白血病微环境中外源物质代谢中的作用的最新概述。
Int J Mol Sci. 2023 Mar 23;24(7):6031. doi: 10.3390/ijms24076031.
6
The Genetic Landscape of Myelodysplastic Neoplasm Progression to Acute Myeloid Leukemia.骨髓增生异常肿瘤向急性髓系白血病进展的遗传学特征。
Int J Mol Sci. 2023 Mar 17;24(6):5734. doi: 10.3390/ijms24065734.
7
Understanding the Continuum between High-Risk Myelodysplastic Syndrome and Acute Myeloid Leukemia.理解高危骨髓增生异常综合征与急性髓系白血病之间的连续统。
Int J Mol Sci. 2023 Mar 6;24(5):5018. doi: 10.3390/ijms24055018.
8
Emerging treatments for myelodysplastic syndromes: Biological rationales and clinical translation.骨髓增生异常综合征的新兴治疗方法:生物学原理与临床转化。
Cell Rep Med. 2023 Feb 21;4(2):100940. doi: 10.1016/j.xcrm.2023.100940. Epub 2023 Feb 13.
9
Clinical Utility of Azacitidine in the Management of Acute Myeloid Leukemia: Update on Patient Selection and Reported Outcomes.阿扎胞苷在急性髓系白血病治疗中的临床应用:患者选择及报告结果的最新进展
Cancer Manag Res. 2022 Dec 23;14:3527-3538. doi: 10.2147/CMAR.S271442. eCollection 2022.
10
Treatment of myelodysplastic syndromes in the era of precision medicine and immunomodulatory drugs: a focus on higher-risk disease.精准医学和免疫调节药物时代骨髓增生异常综合征的治疗:关注高危疾病。
J Hematol Oncol. 2022 Aug 31;15(1):124. doi: 10.1186/s13045-022-01346-9.

本文引用的文献

1
Phase II study of the oral MEK inhibitor selumetinib in advanced acute myelogenous leukemia: a University of Chicago phase II consortium trial.口服 MEK 抑制剂 selumetinib 治疗晚期急性髓系白血病的 II 期研究:芝加哥大学 II 期联盟试验。
Clin Cancer Res. 2014 Jan 15;20(2):490-8. doi: 10.1158/1078-0432.CCR-13-1311. Epub 2013 Oct 31.
2
Next-generation sequencing-based multigene mutational screening for acute myeloid leukemia using MiSeq: applicability for diagnostics and disease monitoring.使用MiSeq对急性髓系白血病进行基于二代测序的多基因突变筛查:在诊断和疾病监测中的适用性
Haematologica. 2014 Mar;99(3):465-73. doi: 10.3324/haematol.2013.093765. Epub 2013 Oct 18.
3
Revised International Prognostic Scoring System (IPSS) predicts survival and leukemic evolution of myelodysplastic syndromes significantly better than IPSS and WHO Prognostic Scoring System: validation by the Gruppo Romano Mielodisplasie Italian Regional Database.修订后的国际预后评分系统(IPSS)比 IPSS 和世界卫生组织预后评分系统更能显著预测骨髓增生异常综合征的生存和白血病演变:意大利罗马米洛迪斯plasia 区域数据库的验证。
J Clin Oncol. 2013 Jul 20;31(21):2671-7. doi: 10.1200/JCO.2012.48.0764. Epub 2013 Jun 24.
4
Dynamic acquisition of FLT3 or RAS alterations drive a subset of patients with lower risk MDS to secondary AML.FLT3或RAS改变的动态获得促使一部分低危骨髓增生异常综合征患者发展为继发性急性髓系白血病。
Leukemia. 2013 Oct;27(10):2081-3. doi: 10.1038/leu.2013.165. Epub 2013 Jun 7.
5
Acquisition of cytogenetic abnormalities in patients with IPSS defined lower-risk myelodysplastic syndrome is associated with poor prognosis and transformation to acute myelogenous leukemia.伴有 IPSS 定义的低危骨髓增生异常综合征患者细胞遗传学异常的获得与不良预后和向急性髓系白血病转化相关。
Am J Hematol. 2013 Oct;88(10):831-7. doi: 10.1002/ajh.23513. Epub 2013 Jul 23.
6
Prognostic impact of RAS mutations in patients with myelodysplastic syndrome.RAS 基因突变对骨髓增生异常综合征患者的预后影响。
Am J Hematol. 2013 May;88(5):365-9. doi: 10.1002/ajh.23410. Epub 2013 Mar 20.
7
FLT3 mutations in myelodysplastic syndrome and chronic myelomonocytic leukemia.FLT3 突变在骨髓增生异常综合征和慢性粒单核细胞白血病中的作用。
Am J Hematol. 2013 Jan;88(1):56-9. doi: 10.1002/ajh.23345. Epub 2012 Oct 31.
8
Validation of a prognostic model and the impact of mutations in patients with lower-risk myelodysplastic syndromes.验证低危骨髓增生异常综合征患者的预后模型和突变的影响。
J Clin Oncol. 2012 Sep 20;30(27):3376-82. doi: 10.1200/JCO.2011.40.7379. Epub 2012 Aug 6.
9
Revised international prognostic scoring system for myelodysplastic syndromes.修订版国际预后积分系统用于骨髓增生异常综合征。
Blood. 2012 Sep 20;120(12):2454-65. doi: 10.1182/blood-2012-03-420489. Epub 2012 Jun 27.
10
Clinical and proteomic characterization of acute myeloid leukemia with mutated RAS.伴有 RAS 基因突变的急性髓系白血病的临床和蛋白质组学特征。
Cancer. 2012 Nov 15;118(22):5550-9. doi: 10.1002/cncr.27596. Epub 2012 May 8.